Navigation Links
Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology

PITTSBURGH, June 30 /PRNewswire/ -- Cellumen, Inc., the Cellular Systems Biology Company, announced today the initiation of a research collaboration with the National Center for Toxicology Research (NCTR), a research center of the Food and Drug Administration (FDA). Under the agreement, Cellumen will use its proprietary CellCiphr(R) toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds including both failed and marketed drugs for the NCTR. The NCTR will incorporate the knowledge generated by Cellumen to develop a liver toxicity knowledge base. Cellumen will use the profiling data and compound safety data from the collaboration to further develop the diversity in the CellCiphr database and the types of cell panels, as well as to advance the classifier informatics tools.

"Failure to predict human toxicity among drug candidates early in the discovery/development process is a leading challenge for the pharmaceutical industry," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "Patients demand and deserve safe and effective drugs, while pharmaceutical companies are increasingly challenged to profitably meet that demand. Cellumen's vision is working toward the goal of replacing animal testing with a human in vitro system in order to facilitate the development of safer, more effective drugs," added Dr. Taylor.

By applying CellCiphr toxicity profiling early in the discovery and lead optimization phases, drug companies will accurately identify compounds with high human toxic liabilities. Actions can be taken to either de-prioritize high-risk compounds, or remove high-risk compounds from a lead series that ultimately would prove to be toxic. Cellumen is at the forefront of drug safety profiling services to aid in predicting drug toxicity early in the discovery/development process.

About Cellumen:

Cellumen is the leading innovator in cellular systems biology (CSB(TM)) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen's CSB solutions are driving "Discovery Toxicology" by addressing the full complexity of disease and safety. Leading global organizations such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, NIH and top pharmaceutical companies partner with Cellumen.

About CellCiphr(R):

CellCiphr is the only cell-based assay solution combining tissue-specific cells, multiplexed functional biomarkers, advanced classifiers, and a compound reference library in order to allow drug developers to accurately identify drug candidates that have high efficacy and low toxicity. CellCiphr is capable of analyzing greater than 10 functional biomarkers per assay that are used as sentinels for analysis of mechanism of action and toxicity of new compounds applied to both rodent and human cells.

SOURCE Cellumen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
2. ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics
5. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
6. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
7. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
8. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
9. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
10. NIH collaborates with EPA to improve the safety testing of chemicals
11. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
Post Your Comments:
(Date:10/12/2015)... de octubre de 2015 El 8 de ... un récord en el congreso con su declaración acerca ... International Plasma Awareness Week (IPAW), que se celebrará del ... por la Plasma Protein Therapeutics Association (PPTA) ... , Aumentar la concienciación mundial acerca de la ...
(Date:10/12/2015)... , October 12, 2015 LabStyle ... Diabetes Management Solution, today announced its Medical Director, Dr. ... study at MobiHealth,s 5th EAI International Conference on ... healthcare through innovations in mobile and wireless technologies," the ... from October 14 - 16, 2015. The ...
(Date:10/12/2015)... ... October 12, 2015 , ... Dr. Carl Peck, MD, ... the firm as a Premier Expert consultant. NDA Partners Premier Experts are ... value to the company's clients. Premier Experts collaborate to design and implement ...
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant Systems, ... launched and multiple surgeries have been completed with this new posterior thoracolumbar spinal ... & Spine Center of the Carolinas. The Revolution™ Spinal System pioneers a ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) ... Recognition Market by Component (Hardware & Software), Product ... Industry (Travel & Immigration, Military & Defense, & ... report to their offering. ... Market worth 3627.90 Million USD by 2020 ...
(Date:10/7/2015)... 8, 2015 --> ... Cards (FPC) during third quarter 2015 amounted to around 960 ... 860 MSEK that was communicated 20 August 2015. ... delivery capacity and a continued growing demand for the company,s ... to be higher than during the third quarter. The revenue ...
(Date:10/2/2015)... ) has ... Law Using Biometrics" report to their offering. ... addition of the "Enforcing the Law Using ... Research and Markets ( ) has ... Law Using Biometrics" report to their offering. ...
Breaking Biology News(10 mins):